首页 | 本学科首页   官方微博 | 高级检索  
     


Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population
Authors:Malekzadeh Reza  Merat Shahin  Derakhshan Mohammad-Hassan  Siavoshi Farideh  Yazdanbod Abbas  Mikaeli Javad  Sotoudemanesh Rasoul  Sotoudeh Masoud  Farahvash Mohammad-Jafar  Nasseri-Moghaddam Siavosh  Pourshams Akram  Dolatshahi Shahab  Abedi Behnoosh  Babaei Masoud  Arshi Shahnam  Majidpour Ali
Affiliation:Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran and Ardabil University of Medical Sciences, Ardabil, Iran.
Abstract:BACKGROUND: In Iran, there is insufficient information on the efficacy of Helicobacter pylori eradication regimens shorter than 10 days. This study aims at assessing the efficacy of 4- and 7-day H. pylori eradication regimens in a high-incidence area of gastric cancer in Iran. METHODS: Subjects with an endoscopic diagnosis of gastritis, positive urease test, and a histological diagnosis of chronic gastritis were enrolled. Patients were randomly assigned to one of three groups: AOC7 (1000 mg amoxicillin, 20 mg omeprazole, and 500 mg clarithromycin twice daily for 7 days), FOT4 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 4 days) and FOT7 (the same treatment as the FOT4 group but for 7 days). Sensitivity to these antibiotics was determined in all isolates recovered from culture. The efficacy of eradication was assessed 8 weeks after the end-of-treatment by the 14C-urea breath test. RESULTS: One hundred and twenty-eight patients were enrolled in the study. Culture was positive for 84 patients and none of these were resistant to amoxicillin, tetracycline or furazolidone, 1.2% were resistant to clarithromycin and 32.1% to metronidazole. Forty-five, 41 and 42 patients were randomly allocated to the AOC7, FOT4, and FOT7 groups, respectively. The intention-to-treat eradication rates were 35.5, 17.1, and 23.8% for the AOC7, FOT4, and FOT7 groups, respectively. CONCLUSION: Treatment regimens of 4 or 7 days are unacceptable for H. pylori infection in Iran, even in the presence of a favorable sensitivity profile.
Keywords:Helicobacter pylori    Iran    therapeutics
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号